Abstracts tagged "Native Americans"

Abstract Number: 1688 • 2012 ACR/ARHP Annual Meeting
Evolution of Preclinical Autoimmunity in Individuals At Risk for Development of Rheumatoid Arthritis
Hani S. El-Gabalawy¹, David B. Robinson¹, Irene Smolik¹, Donna M. Hart¹, Elizabeth D. Ferucci², Marianna M. Newkirk³, Marvin J. Fritzler⁴, Catriona Cramb⁵, Jeremy Sokolove⁶ and William H. Robinson⁷, ¹Arthritis Centre, University of Manitoba, Winnipeg, MB, Canada, ²Division of Community Health Services, Alaska Native Tribal Health Consortium, Anchorage, AK, ³Medicine, McGill University Health Centr, Montreal, QC, Canada, ⁴Medicine, University of Calgary, Calgary, AB, Canada, ⁵CCSR 4135 Immunology Rheumatol, Stanford University, Palo Alto, CA, ⁶Medicine, Stanford University, Palo Alto, CA, ⁷Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, CA
Background/Purpose: Rheumatoid arthritis (RA) is prevalent, severe, and predominantly seropositive in many North American Native (NAN) populations. We have shown a strong tendency towards familial…
Abstract Number: 1194 • 2012 ACR/ARHP Annual Meeting
Prevalence of Anti-Peptidylarginine Deiminase Type 4 Antibodies in Rheumatoid Arthritis and Unaffected First-Degree Relatives in Indigenous North American Populations
Elizabeth D. Ferucci¹, Irene Smolik², Tammy L. Choromanski³, David B. Robinson⁴, Marianna M. Newkirk⁵, Marvin J. Fritzler⁶, Antony Rosen⁷, Erika Darrah⁸ and Hani S. El-Gabalawy⁴, ¹Division of Community Health Services, Alaska Native Tribal Health Consortium, Anchorage, AK, ²Arthritis Center, University of Manitoba, Winnipeg, MB, Canada, ³Alaska Native Tribal Health Consortium, Anchorage, AK, ⁴Arthritis Centre, University of Manitoba, Winnipeg, MB, Canada, ⁵Medicine, McGill University Health Centr, Montreal, QC, Canada, ⁶Medicine, University of Calgary, Calgary, AB, Canada, ⁷Division of Rheumatology, Johns Hopkins University, Baltimore, MD, ⁸Division of Rheumatology, The Johns Hopkins University, Baltimore, MD
Background/Purpose: Antibodies directed against peptidylarginine deiminase type 4 (PAD-4) are present in a subset of patients with rheumatoid arthritis (RA) and are associated with more…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].